Hao Sun China


Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.
Website:
Null
Partnering Objectives
Headquartner in China
Wuxi Biocity
General manager assistant 

LIBER Sun China

以尖端生命科学技术转化为核心,专注于ReproCore超微因子系列生物制品的研发、生产、销售、服务为主营业务,涉及医学康养、医学美容、健康调理、精准医疗等领域,以严谨的科学态度、严格的技术标准、完备的质量保障、一流的产品服务,致力于为广大消费者,特别是社会高端人群打造全生命周期的个性化健康定制咨询、产品、服务、管理于一体的健康生态平台。
Partnering Objectives
Headquartner in China
京美瑞禾健康产业集团
副总经理 

Amy Sung China

Big Pharma
Website:
sanofi
Company Size (Fulltime employees)
Please specify your partnering goal
understand the mkt
Headquartner in China
Biotech/Pharma Category
Sanofi
Sr launch excellence manager 

Chen Suo China

华润集团一级利润中心,聚焦生命科学领域投资与合作
Partnering Objectives
Headquartner in China
华润生命科学集团
Director 

Ms. Yeqing Tan China

Genetron
Website:
www.g
Company Size (Fulltime employees)
Please specify your partnering goal
visiting
Headquartner in China
Genetronhealth
Marketing 

Jun Tang China

WuXi Apptec provides a broad portfolio of R&D and manufacturing service that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.
Partnering Objectives
Headquartner in China
WuXi Apptec (chengdu)
Managing Product Team 

Mrs. Echo Tang China

Haisco focus on the innovative drugs and the high-end drugs, and we seek collaborative partners for the previous drugs.
Website:
www.haisco.com
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
The partners develope the innovative and the high-end drugs.
Headquartner in China
Haisco Pharmaceutical group
BD manager 
Functionality

Dr. Jason Tang China

EpimAb's innovative FIT-Ig technology offers a game-changing approach to a broad variety of bi-specific antibodies. The technology provides access to stable bi-specifics by applying conventional molecular biology techniques. FIT-Ig molecules demonstrate properties similar to therapeutically active antibodies. They are actually manufactured like antibodies using standard processes at yields and purities similar to antibodies, e.g. EMB01, our first candidate was developed from cell line to IND submission date in 15 months, produced 3,5 g/l in a standard cell line and was easily purified with 70% recovery. Further candidates are manufactured with even higher yields.

EpimAb is developing a portfolio of bispecific antibodies for the treatment of different oncology indications. The first asset, EMB01, a first in class dual c-Met and EGFR inhibitor, is currently being investigated in a PhI/II study for treatment of solid tumors.

EMB02 (IND filing Q2/2020) and EMB04 are immune oncology biologics and EMB06 (IND filing Q4/2020) is a bispecific T-cell engager. In addition EMB08 (IND filing 2021) is a bispecific fusion protein.

EpimAb is committed to diversifying its portfolio of FIT-Igs in order to further validate the flexibility and robustness of the format and its platform. The broad applicability of this technology enables EpimAb to pursue two concurrent strategies for commercializing the technology:

•      Grant licenses to other pharmaceutical companies to combine two antibodies into a FIT-Ig themselves. Through this initiative EpimAb intends to catalyze the broad use of FIT-Igs for the benefit of scientists, the medical community and eventually patients; and

•      Create and develop proprietary FIT-Igs enabling EpimAb to grow and develop a discovery and development organization, generate FIT-Igs of great value to patients and medical experts and also improve its technological approach to bi-specific antibodies for the benefit of the scientific community.

Partnering Objectives
Biotech/Pharma Category
Assets Information 1
EMB-01
Assets Information 2
EMB-02
Assets Information 3
EMB-06
Biotech/Pharma Asset Stage
Dr. Jason Tang
EpimAb Biotherapeutics
BD Director 

Ms. Sally Tang China

CRO based in Shanghai
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Working with clients with preclinical R&D needs
Headquartner in China
Shanghai Medicilon
Director of Business Development 

Weiming Tang China

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Looking for appropriate opportunities to in-license
Headquartner in China
Weiming Tang
I-Mab Biopharma
Global Business Head and Executive VP